希罗达联合奥沙利铂治疗晚期大肠癌17例临床观察

目的:观察希罗达联合奥沙利铂治疗晚期大肠癌的疗效与不良反应。方法:17例晚期大肠癌患者采用希罗达2500mg/(m2·d),分两次口服,第1～14天,休息7天。奥沙利铂130mg/m2 5%葡萄糖注射液500ml中静脉滴注2小时,第一天,21天为1周期,连用2周期以上评价疗效及不良反应。结果:15例中完全缓解(CR)1例,部分缓解(PR)7例,稳定(SD)5例,进展(PD)4例。有效率(RR)47.1%。不良反应主要为胃肠道反应,骨髓抑制,手足综合征,末梢神经炎,口腔黏膜炎。结论:希罗达联合奥沙利铂治疗晚期大肠癌的疗效确切,不良反应小,患者可以耐受。

Capecitabine combined with oxaliplatin in advanced colorectal cancer

Objective:To observe the therapeutic effect and toxicity of capecitabine combined with oxaliplatin in the treatment of advanced colorectal cancer.Methods:15 cases were treated with capecitabine 2 500 mg/m2 per day in 2 equally divided doses orally for 1~14 days at an interval of 7 days,oxalipatin 130 mg/m2 in 5% Glucose 500 ml intravenous drip within 2 hours in the first day at an interval of 2 weeks.The period of treatment was 21 days for 2 or more,the therapeutic effect and toxicity were evaluated after treatment.Results:Of 15 patients with advanced colorectal cancer,1 was complete remission(CR),7 partial remission(PR),5 steadiness(SD),4 progression(PD),the effective rate was 47.1%.The main toxic reactions were gastrointestinal reaction,arrest of bone marrow,hand-foot syndrome,peripheral nerve toxicity and oral mucositis.Conclusion:Capecitabine combined with oxaliplatin is an effective,better-tolerated and alternative therapeutic method in advanced colorectal cancer.